Kyowa Kirin
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kyowa Kirin sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
Kyowa Kirin: 34 sponsored US clinical trials, 1 recruiting.
Kyowa Kirin sponsors 34 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 27 completed. 8 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson's Disease, with 2 trials.
Top-decile sponsor footprint
Kyowa Kirin ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
34 total, page 1 of 1
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
NCT04014374
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
NCT04745234
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
NCT07192471
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
NCT05027646
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
NCT04190654
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
NCT03915405
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
NCT04147910
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
NCT03703102
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
NCT02915705
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT02867007
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
NCT02647866
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
NCT02750618
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
NCT02705105
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
NCT02537431
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
NCT02526160
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
NCT02304367
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
NCT02312687
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
NCT02358473
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
NCT02301130
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
NCT02163577
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
NCT01728805
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
NCT01626664
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
NCT00575562
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
NCT00346632
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
NCT00199381
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
NCT00199446
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
NCT00199433
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
NCT00199342
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
NCT00199368
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
NCT00199420
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
NCT00199407
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
NCT00955045
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
NCT00456586
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
NCT00456794
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 13 |
| Phase 3 | 8 |
What is open in the Kyowa Kirin pipeline
1 recruiting of 34 indexed (3% open); 27 completed (79%).
Phase mix: 8 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Parkinson's Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kyowa Kirin: open-pipeline peers nationwide
Peers matched on 34 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Kyowa Kirin sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 trials (± recruiting share)
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- American Regent · 34 trials · 0% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
Related
What to do with this Kyowa Kirin page
34 registered trials is a research-attention snapshot, not an endorsement of Kyowa Kirin or any single study.
- 1 of Kyowa Kirin's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinson's Disease is the condition Kyowa Kirin studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kyowa Kirin pipeline card: 34 registered trials from official public datasets.Report a data error.